PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pfizer Inc (PFE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has a high dividend yield and some positive developments in its pipeline, the company is facing significant revenue headwinds, weak financial performance, and limited near-term catalysts. The technical indicators show a neutral to slightly bullish trend, but the lack of strong proprietary trading signals and mixed analyst ratings suggest holding off on buying this stock right now.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 65.346, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 26.591, and resistance is at 27.634. The stock is trading slightly below resistance levels in pre-market, showing limited upside in the short term.
Positive analyst upgrades from Guggenheim, HSBC, and Argus, with price targets ranging from $32 to $
High dividend yield of 6%, which is above the peer average.
Potential interest in Pfizer as an acquirer in the blood cancer drug market, following Merck's acquisition of Terns.
Significant revenue headwinds with $15B-$20B in revenues at risk due to loss of exclusivity through
Weak financial performance in Q4 2025, with revenue down -1.16% YoY, net income down -501.95% YoY, and EPS down -514.29% YoY.
Mixed analyst ratings, with some firms assigning Underperform or Neutral ratings and price targets as low as $
Limited near-term catalysts and uncertainty in the macroeconomic environment.
In Q4 2025, Pfizer reported a revenue decline of -1.16% YoY to $17.56 billion. Net income dropped significantly to -$1.65 billion, down -501.95% YoY. EPS fell to -$0.29, a decline of -514.29% YoY. However, gross margin improved to 64.15%, up 6.00% YoY, indicating some operational efficiency gains.
Analyst ratings are mixed. Guggenheim, HSBC, and Argus have Buy ratings with price targets ranging from $32 to $36, citing pipeline developments and long-term growth potential. However, RBC Capital and Barclays have Underperform/Underweight ratings with a $25 price target, citing revenue cliffs and limited near-term visibility.
